BAFNAPH Stock View

Bafna Pharmaceuticals Ltd

₹ 87.95

icon -4.70 | -4.98
Market Cap ₹( Cr.)
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
Proj. Revenue ( Cr.)

Stock View

Last Updated On.

The average score for Bafna Pharmaceuticals Ltd stands at against 4, three months back.

Bafna Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing finished pharmaceutical formulations. It is also involved in manufacturing 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. It supplies its products to the United Kingdom, Europe, and Australian markets. The Company's Grantlyon facility has the capability to supply both small-scale clinical trial quantities and commercial-scale requirements.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data

50 DMA(₹)
100 DMA(₹)
200 DMA(₹)
52 Weeks Range
78.51     125.55

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required